Curative by Design™
Creating a novel cancer immunotherapy is both and an art and science that requires far more than academic knowledge. Having learned from the pioneering achievement of advancing the first
FDA-approval of a living cell therapy to market, Verik’s founders
are poised to succeed once again with the help of a team of experienced, savvy professionals.
Nancy L. Parenteau, Ph.D.
Co-founder, Chair, President and CSO more
Joseph C. Laning, Ph.D.
Co-founder, VP Molecular Immunology more
Janet H. Young, Ph.D.
Co-founder, VP Translational Biology more
Susan J. Sullivan, Ph.D.
VP Operations more